28th Jun 2006 16:32
PROTEOME SCIENCES plc PRESS RELEASE Licence Agreement in HTS Stroke June 28, 2006. Proteome Sciences plc ("Proteome Sciences") is pleased toannounce a licence agreement with one of the top 10 global leaders in clinicaldiagnostics to use its biomarkers for the detection, diagnosis and monitoringof stroke. This is a new area for the licencee who has determined not todisclose its identity at this time for competitive reasons. The biomarkers werediscovered and validated using a combination of different proteomic approachesavailable for external use through the proprietary ProteoSHOP‚® platform.Stroke is the brain equivalent of a heart attack. Blood must flow in andthrough the brain for it to function. If its flow is obstructed by a blood clotmoving to the brain or by narrowing or blocking of blood vessels, the brainloses its energy supply, causing damage to tissues leading to stroke.Annually, 15 million people worldwide suffer a stroke. Of these, 5.5 milliondie and another 5 million are left permanently disabled, placing a burden onfamily and community.Stroke is the third leading cause of death in the US (160,000 deaths) withannual costs of $57.9bn for stroke-medical related costs and disability and thesingle most common cause of severe disability. 750,000 people are diagnosed inthe US annually having new or recent strokes.Under the research licence, a number of Proteome Sciences biomarkers will betested in stroke for inclusion on a new panel for the licencee'shigh-throughput diagnostic platforms. No financial details were disclosed.The preliminary announcement of Proteome Sciences results for the year ended31st December, 2005 will be released by 30th June, 2006.Christopher Pearce, CEO of Proteome Sciences, said:" This licencee is world renowned in clinical diagnostics and has built astrong customer base ideally placed to introduce and support new strokediagnostic products globally. This reflects their commitment to developinnovative assays and solutions to address the major unmet diagnostic andprognostic needs in stroke.They have been impressed by Proteome Sciences' ProteoSHOP‚® technology todiscover novel biomarkers in blood and to progress these rapidly for the marketplace. This agreement brings important new biomarkers to their IVD pipeline andthe opportunity to diagnose stroke in a high- throughput system. We lookforward to incorporation of our stroke markers onto their systems and to arapid introduction of an HTS stroke test." - Ends - Notes to Editors:StrokeStroke is the brain equivalent of a heart attack. Blood must flow in andthrough the brain for it to function. If its flow is obstructed by a blood clotmoving to the brain or by narrowing or blocking of blood vessels, the brainloses its energy supply, causing damage to tissues leading to stroke.Annually, 15 million people worldwide suffer a stroke. Of these, 5.5 milliondie and another 5 million are left permanently disabled, placing a burden onfamily and community.Stroke is the third leading cause of death in the US (160,000 deaths) withannual costs of $57.9bn for stroke-medical related costs and disability and isthe single most common cause of severe disability. 750,000 people are diagnosedin the US annually having new or recent strokes.Proteome Sciences plcProteome Sciences plc, a global leader in applied proteomics, uses highsensitivity proprietary technologies to detect differentially expressedproteins in diseases. The protein biomarkers discovered in body fluids ortissues are validated, developed and commercialised as diagnostic, prognosticor therapeutic products through strategic alliances and out-licensing.Through its unique ProteoSHOP‚® toolbox, Proteome Sciences provides highsensitivity/high throughput proteomics solutions, including traditional twodimensional gel-based electrophoresis (2DE) and proprietary gel-free proteinsequence tag technologies (PST‚®, qPST¢â€ž¢ & TMT‚®), to major pharma, biotechnologyand diagnostic companies, to discover and exploit protein biomarkers. Chemicalmass tags for isobaric labelling have been developed as stand-alone reagents.For further information please visit www.proteomics.comEnquiries:Proteome Sciences plcChristopher Pearce Chief ExecutiveJames Malthouse Finance DirectorTel: +44 (0)1932 865065Fax: +44 (0)1932 868969Email: [email protected] Relations for Proteome SciencesIKON AssociatesAdrian ShawTel: +44 (0)1483 535102Mobile: +44 (0)797 9900733Email: [email protected] SCIENCES PLCRelated Shares:
Proteome